- Home
- RDFN vs SPRY Comparison
RDFN vs SPRY Comparison
Compare RDFN & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDFN
- SPRY
- Stock Information
- Founded
- RDFN 2002
- SPRY 2015
- Country
- RDFN United States
- SPRY United States
- Employees
- RDFN N/A
- SPRY N/A
- Industry
- RDFN Real Estate
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- RDFN Finance
- SPRY Health Care
- Exchange
- RDFN Nasdaq
- SPRY Nasdaq
- Market Cap
- RDFN 1.1B
- SPRY 1.1B
- IPO Year
- RDFN 2017
- SPRY N/A
- Fundamental
- Price
- RDFN $7.94
- SPRY $12.95
- Analyst Decision
- RDFN Hold
- SPRY Strong Buy
- Analyst Count
- RDFN 11
- SPRY 4
- Target Price
- RDFN $9.43
- SPRY $26.00
- AVG Volume (30 Days)
- RDFN 4.4M
- SPRY 1.4M
- Earning Date
- RDFN 02-25-2025
- SPRY 03-20-2025
- Dividend Yield
- RDFN N/A
- SPRY N/A
- EPS Growth
- RDFN N/A
- SPRY N/A
- EPS
- RDFN N/A
- SPRY N/A
- Revenue
- RDFN $1,016,774,000.00
- SPRY $2,568,000.00
- Revenue This Year
- RDFN $8.63
- SPRY $67,363.34
- Revenue Next Year
- RDFN $9.90
- SPRY $511.99
- P/E Ratio
- RDFN N/A
- SPRY N/A
- Revenue Growth
- RDFN 3.70
- SPRY 8460.00
- 52 Week Low
- RDFN $5.10
- SPRY $6.29
- 52 Week High
- RDFN $15.29
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- RDFN 47.54
- SPRY 44.57
- Support Level
- RDFN $7.58
- SPRY $11.00
- Resistance Level
- RDFN $8.78
- SPRY $14.87
- Average True Range (ATR)
- RDFN 0.45
- SPRY 0.95
- MACD
- RDFN 0.05
- SPRY 0.04
- Stochastic Oscillator
- RDFN 34.17
- SPRY 31.26
About RDFN Redfin Corporation
Redfin Corp is a residential real estate broker. It pairs its agents with the technology to create a service that is faster and costs less. The company meets customers through a listings-search website and mobile application. The company uses the same combination of technology and local service to originate mortgage loans and offer title and settlement services. It has five operating segments and three reportable segments, real estate services, rentals, and mortgage. The company generates the majority of its revenue from Real estate services.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.